The
World Health Organisation estimates
that 100 million people worldwide
suffer from asthma.
Chronic obstructive
pulmonary disease (COPD) is the fourth
greatest cause of death worldwide.
The management of respiratory diseases
such as these remains a major healthcare
challenge.
Our asthma range
includes Pulmicort, one of the world’s
leading asthma medicines and Symbicort,
a new therapy that enables doctors
to tailor a patient’s treatment of
this variable disease with a single
inhaler. The Turbuhaler dry-powder
inhaler is another key feature of
our portfolio.
The toll of pollution
and stress is rising in India and
the incidence of asthma, bronchitis
and other lung diseases are growing
at an alarming pace. AstraZeneca markets
a wide range of products for the treatment
of respiratory disease such as asthma
and rhinitis. We have a range of products
like ‘Bricanyl’ & ‘Theobric’ tablets,
‘Bricarex’ expectorant and tablets,
‘Linctus Codeine’ and ‘Mits Linctus’
cough syrups, ‘Pulmicort’ inhalers
and ‘Rhinocort’ nasal spray. Research
is focused on developing therapies
for the inflammatory diseases of the
respiratory system (rhinitis, asthma
and chronic obstructive pulmonary
disease (COPD)) and of the musculo-skeletal
system (rheumatoid arthritis).
Key
Products
More information
about our products is available by
clicking on the product names below.
.gif) Bricanyl
Tablets (Terbutaline Sulphate)
Bricanyl
Injection (Terbutaline Sulphate)
Bricanyl
Durules (Terbutaline Sulphate)
Bricanyl
Syrup (Terbutaline Sulphate)
Bricanyl
Inhaler (Terbutaline Sulphate)
Bricanyl
Nebulising Solution (Terbutaline
Sulphate)
Bricarex
(Terbutaline/Guaifenesin )
Linctus
Codeinae (Codeinae)
Pulmicort
(Budesonide)
Rhinocort
(Budesonide)
Symbicort
(Budesonide/formoterol)
|